A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02912533

Enrollment

Unknown

Registered

2016-09-23

Start date

2016-09-30

Completion date

2018-03-31

Last updated

2019-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia

Brief summary

The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Interventions

DRUGJR-131

Study design

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Inclusion criteria

* Patients being treated with erythropoiesis stimulating agent.

Exclusion criteria

* Patients having complication or history of a cardiovascular / lung / brain infarction. * Patients having a pronounced hemorrhagic lesion.

Design outcomes

Primary

Measure	Time frame
Measure adverse events	52 weeks

Secondary

Measure	Time frame
Hemoglobin level	52 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026